COMMUNIQUÉS West-GlobeNewswire

Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
09/11/2018
--Well tolerated; dose dependent biological effects consistent with CD40-mediated immune cell activity-- --Program development expanded based on results observed to date-- HAMPTON, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE [...]
Achaogen Announces Presentations at Two Investor Healthcare Conferences in November
09/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug [...]
Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
09/11/2018
– Management Hosting Webcast of Key Opinion Leader Discussion Today at 6:00 p.m. ET – CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company [...]
Arsanis Reports Financial Results for Third Quarter 2018
09/11/2018
WALTHAM, Mass. and VIENNA, Austria, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address [...]
NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumor Microenvironment at SITC 2018
09/11/2018
AMES, Iowa, Nov. 09, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that data from three separate trials are being presented at the Society for Immunotherapy of Cancer (SITC) Annual [...]
Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual Meeting
09/11/2018
Antigen Seeding Technology (AST) is a Potent and Complimentary Addition to Company’s Engineered Toxin Bodies (ETB) Technology AUSTIN, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM), a [...]
Chembio to Participate in Upcoming Investor Conferences
09/11/2018
MEDFORD, N.Y., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced plans to participate in two upcoming [...]
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
09/11/2018
NK cell potency and persistence significantly improved using cell engineering technology 60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cells Single in vivo administration of [...]
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
09/11/2018
Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage Solid Tumors REDWOOD CITY, Calif. and WASHINGTON, Nov. 09, 2018 (GLOBE NEWSWIRE [...]
CytomX Therapeutics Presents CX-072 Clinical Translational Data at 2018 SITC Annual Meeting
09/11/2018
- Demonstrates Further Proof-of-Mechanism of Probody ™ Platform – - Consistent with CX-072 Clinical Observations at 2018 ASCO and ESMO Presentations- - Company to Host Analyst and Investor Event and Webcast Tomorrow, [...]
Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
09/11/2018
CUE-101 Demonstrates Selective Binding and Preferential Activation/Expansion of Antigen-specific T Cells, Inhibition of Tumor Growth as Monotherapy and in Combination with a PD-1 Inhibitor CAMBRIDGE, Mass., Nov. 09, [...]
Progressive Care to Host Conference Call on Third Quarter 2018 Financial Results and Business Update on November 14th
09/11/2018
MIAMI, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, is pleased to announce that the Company has scheduled an investor conference call [...]
Immune Design to Present at Jefferies 2018 London Healthcare Conference
09/11/2018
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos Paya, M.D., Ph.D., [...]
Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results
09/11/2018
-- Presented Updated Data from Phase 2 Basket Studies in Bardet-Biedl Syndrome (BBS) and Alström Syndrome at the 57 th Annual European Society for Pediatric Endocrinology (ESPE) Meeting -- -- Launched TEMPO Registry for [...]
Spring Bank Announces Additional Inarigivir Results at AASLD Conference
09/11/2018
*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted *New data from ACHIEVE trial demonstrates that increased baseline serum IP-10, a [...]
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy
09/11/2018
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, Renders Resistant Solid Tumors Vulnerable to PD1 Blockade Isoform- [...]
Solid Biosciences to Present at the Credit Suisse Healthcare Conference
09/11/2018
CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27 th Annual Healthcare Conference on Wednesday, November 14, [...]
Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas
09/11/2018
Data presented at Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting demonstrate ADU-S100 (MIW815) is well-tolerated with no dose-limiting toxicities reported Preliminary signs of clinical and biomarker [...]
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
09/11/2018
New Phase 3 Trial of Tonmya® for the Treatment of PTSD to Commence First Quarter 2019 NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix or the Company), a clinical- [...]

Pages